Premium
Five‐Year Results of a Randomized Trial Comparing De Novo Sirolimus and Cyclosporine in Renal Transplantation: The Spiesser Study
Author(s) -
Lebranchu Y.,
Snanoudj R.,
Toupance O.,
Weestel P.F.,
de Ligny B. Hurault,
Buchler M.,
Rerolle J.P.,
Thierry A.,
Moulin B.,
Subra J.F.,
Deteix P.,
Pogamp P. Le,
Finzi L.,
Etienne I.
Publication year - 2012
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2012.04036.x
Subject(s) - medicine , calcineurin , discontinuation , adverse effect , transplantation , sirolimus , randomized controlled trial , kidney transplantation , regimen , renal function , urology , immunosuppression , surgery , gastroenterology
Calcineurin inhibitors improve acute rejection rates and short‐term graft survival in renal transplantation, but their continuous use may be deleterious. We evaluated the 5‐year outcomes of sirolimus (SRL) versus cyclosporine (CsA) immunosuppressive treatment. This observational study was an extension of the SPIESSER study where deceased donor kidney transplant recipients were randomized before transplantation to a SRL‐ or CsA‐based regimen and followed up 1 year. Data from 131 (63 SRL, 68 CsA) out of 133 patients living with a functional graft at 1 year were collected retrospectively at 5 years posttransplant. Seventy percent of CsA patients versus 54% of SRL patients were still on the allocated treatment at 5 years (p = 0.091), most discontinuations in each group being due to safety issues. In intent‐to‐treat, mean MDRD eGFR was higher with SRL: 54.2 versus 45.3 mL/min with CsA (p = 0.019); SRL advantage was greater in on‐treatment analyses. There were no differences for patient survival (p = 0.873), graft survival (p = 0.121) and acute rejection (p = 0.284). Adverse events were more frequent with SRL (80% vs. 60%, p = 0.015). Results confirmed the high SRL discontinuation rate due to adverse events. Nevertheless, a benefit was evidenced on renal function in patients (more than 50%) still on treatment at 5 years.